HealthNews Pulse
Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.
Read the full pulseContinue in Briflio to read, react, comment, and share.
Sources